Clinical trial Recruiting at 2 sites Interventional Ages 5 to 17

Post-market follow-up of the NEMOST V2 spinal implant

Official title: Post-market Clinical Follow-up Study of NEMOST V2 Growing Domino

Run by Euros · NCT07403084 · Data updated 2026-11-12

This project will try the NEMOST V2 growing domino in children aged 5–17 with progressive scoliosis to track safety and device performance over five years.

More Scoliosis Idiopathic trials

Quick facts

Study typeInterventional
Ages5 Years to 17 Years
SexAll
Enrollment140 (estimated)
SponsorEuros
Industry-sponsored
Locations5 sites (Nice, Provence-Alpes-Côte d'Azur Region and 4 other locations)
StatusRecruiting
StartedDecember 19, 2025
Main results expectedDecember 19, 2033
Study endsDecember 19, 2033
Registry record updatedFebruary 11, 2026
Trial IDNCT07403084 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 5–17 with progressive idiopathic, congenital, neuromuscular, or syndromic scoliosis who require primary surgical intervention and whose parents or guardians consent.

Probably not a fit

Patients with local inflammation or active infection, pathological obesity, non-reducible scoliosis, allergy to implant materials, insufficient tissue coverage, or prior spinal instrumentation/fusion are unlikely to benefit from this implant.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, non-randomized post-market surveillance will collect retrospective and prospective clinical and radiological data on 140 children treated with the NEMOST V2 growing domino for progressive scoliosis. Participants aged 5–17 with idiopathic, congenital, neuromuscular, or syndromic scoliosis requiring primary surgical intervention will be enrolled at three French centers. The study is interventional but uncontrolled, and follows patients for five years after surgery to record complications (primary objective) and device performance (secondary objective). Clinical exams and imaging at scheduled postoperative intervals will be used to characterize safety events and the long-term behavior of the implant.

Why it matters

Potential benefit: If successful, the study could confirm that NEMOST V2 controls spinal curvature while allowing growth and has an acceptable safety profile, potentially reducing the need for additional procedures.

How similar studies have gone: Other growth-friendly spinal devices (growing rods, VEPTR, magnetically controlled rods) have shown mixed success with known complication profiles, while NEMOST-specific long-term data remain limited beyond its market release.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Idiopathic, congenital, neuromuscular, or syndromic scoliosis : Progressive spinal deformity not managed by orthopedic treatment, and requiring primary surgical intervention.
* The patient, as well as their parents or legal guardians, are informed of the participation in the study.
* Patients aged from 5 to 17 yeas old, excepted the one who still have a potential for growth

Exclusion Criteria:

* signs of local inflammation;
* acute or chronic, local or systemic infections ;
* non-reducible scoliosis ;
* pathological obesity ;
* allergy or intolerance to implanted materials;
* insufficiency or absence of tissue coverage. The NEMOST implant should not be used in a spine that has already been instrumented or fused.

Where it's running

  • Hopital Lenval Nice
    Nice, Provence-Alpes-Côte d'Azur Region, France
    Recruiting
  • CHU Pellegrin
    Bordeaux, France
    Recruiting
  • Hospices Civils de Lyon
    Lyon, France
    Not yet recruiting
  • Hopital Armand Trousseau
    Paris, France
    Not yet recruiting
  • Hopital Necker
    Paris, France
    Not yet recruiting

Study contacts

  • Principal investigator: Federico Solla, MD — Centre Hospitalier Universitaire de Nice
  • Study coordinator: Célia Armanet, PHD
  • Email: carmanet@euros.fr
  • Phone: +330756848896

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.